Acoramidis News Today

Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Armed with strong phase III safety data in Japanese patients, Palo Alto, Calif.-based Bridgebio Pharma Inc. is planning to file for Japan approval of its investigational drug acoramidis for a rare heart disorder.

1. In this randomized controlled trial, patients with transthyretin (TTR) amyloid cardiomyopathy exposed to acoramidis had slower disease progression than those on a placebo. 2. There were significantly fewer adverse events in the acoramidis group, along with a higher quality of life. Evidence Rating Level: 1 (Excellent) Study Rundown: TTR is a transport protein with

BridgeBio will receive $500 million in exchange for royalties from sales of acoramidis, a drug currently under FDA review for treating heart complications caused by the rare disease transthyretin amyloidosis. The deal also refinances lending agreements, providing BridgeBio with access to additional capital.

A study shows that patients with transthryretin amyloid cardiomyopathy benefited significantly when they took the drug Acoramidis.

BridgeBio Pharma, Inc. (BBIO) has submitted an NDA for acoramidis to the FDA for the treatment of Transthyretin Amyloid Cardiomyopathy or ATTR-CM. The application was based on positive results from ATTRibute-CM, the Phase 3 study.

With BridgeBio Pharma Inc. expecting to complete a regulatory submission prior to the close of 2023, the 30-month results of ATTRibute-CM provide the most comprehensive overview yet of the benefit-risk profile for acoramidis in ATTR-CM.

A new drug for transthyretin amyloid cardiomyopathy significantly increases survival and reduces hospitalizations, according to a study.

BridgeBio reported its drug acoramidis missed the main goal of a pivotal study in patients with transthyretin amyloidosis affecting the heart—the same type of patients helped by a currently approved blockbuster Pfizer drug. BridgeBio attributed the trial failure to a surprisingly strong placebo response, and it will continue the study, hoping for better outcomes on additional goals.